Biogen investors have been on a wild ride over the last year, and on Wednesday they experienced their first major jolt in 2020. It was a welcome one.
The company prevailed in a high-stakes patent challenge from Mylan, giving Biogen a win as it continues defending its big-selling multiple sclerosis drug Tecfidera from would-be copycats.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,